Vaxzevria targets Omicron variant with preliminary positive data

Recently, AstraZeneca reported data from a trial of its vaccine Vaxzevria against a variant of Omicron
.

Results from the immunogenicity and safety trial D7220C00001 showed that the vaccine produced higher antibody responses to the Omicron variant, as well as other variants, including Beta, Delta, Alpha and Gamma, according to Reuters
.

AstraZeneca reported an increase in responses in people who had previously been vaccinated with Vaxzevria or the mRNA vaccine
.
They added that, given the current need for booster doses, they will submit these data to global regulators
.

AstraZeneca developed Vaxzevria with researchers at Oxford University, and lab studies last month found that three doses of Vaxzevria were effective against Omicron
.

Vaxzevria consists of a virus (adenovirus) that has been modified to contain the genes that make the SARS-CoV-2 virus
.
Once injected, the vaccine delivers the SARS-CoV-2 gene into cells and into the body
.
Cells will use this gene to produce the spike protein
.
The individual's immune system then recognizes this protein as foreign and produces antibodies in response, activating T cells to attack it
.

In December 2021, a major UK trial found that AstraZeneca's vaccine increased antibody levels when given as a booster after an initial vaccination with its own vaccine or a vaccine based on mRNA technology
.
Still, the study concluded that mRNA vaccines made by Pfizer and Moderna had the greatest boost to antibodies at booster doses
.
Andrew Pollard, head of the Oxford Vaccine Group, commented: "These important studies show that a third dose of Vaxzevria strongly enhances immunity to COVID-19 following two initial doses of the same vaccine, or following either an mRNA or an inactivated vaccine.
force" .

Original source:

https:// href="https://" target="_blank" rel="noopener">https:// https://

Leave a comment here